Exelixis Patent Company LLC

Exelixis, Inc.

Shao Po Lu

Raju Mohan

Edwin J Schweiger

William C Stevens, Jr

Yinong Xie

Richard Martin

Brett Bradley Busch

Michael Charles Nyman

Tie-Lin Wang

Brenton Todd Flatt

Xiao-Hui Gu

Wei Xu

Vasu Jammalamadaka

Alan Thomas Johnson

Brant Clayton Boren

Haixia Wang

Christopher D Bayne

Xiao Hui Gu

Tie Lin Wang

Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.

Imidazole based LXR modulators

Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

Modulators of LXR

Compounds of the invention, such as compounds of formula (I): 

Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R, R, R, R, J, J, G, G, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

LXR and FXR modulators

Growing community of inventors

San Diego, CA, United States of America

Shao Po Lu